TNFSF11 and osteoporosis: Considering that RANKL‐RANK signaling regulates the differentiation and activity of osteoclasts and the application of Denosumab (human anti‐RANKL mAb) in clinical therapies of osteoporosis reducing bone loss caused by bacterial infections, designing and estimating a novel vaccine targeting the RANKL is theoretically possible.25